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Atrial fibrillation (AF) is the most common arrhythmia and may be complicated by embolic 
stroke. It is also associated with a significant risk of heart failure and mortality. The burden  
of rheumatic heart disease remains great in the developing world. The prevalence of AF in 
those with rheumatic heart disease is in the order of 20% with a resultant 17-fold increased 
risk of embolic stroke.  
Over time, many other risk factors for stroke in the AF population have been described. 
Stroke risk stratification tools such as the CHADS2 (Congestive heart failure, hypertension, 
age of 75 or older, diabetes mellitus or stroke/TIA) and CHA2DS2VASc (with the addition of 
a second age category, female gender, and peripheral artery disease) scores have been 
developed. These are used to assess the need for anticoagulation and have been well  
validated. These scores have traditionally excluded those patients with valvular AF. 
Valvular AF has not been studied extensively in the contemporary era. Oral anticoagulation 
had previously been advised in all patients with valvular AF. Little is known however about 
outcomes for stroke and mortality in this cohort of patients. Furthermore, the utilization of  
the CHADS2 and CHA2DS2VASc scores may provide incremental benefit in prognostication 
and resultantly, both more diligent prescription of anticoagulation and improved outcomes. 
Objectives 
The objectives of this study were as follows - 
1. To determine the prevalence of AF in the Global Rheumatic Heart Disease Registry (the
REMEDY study) and in the Groote Schuur Hospital (GSH) cohort.
2. To assess the demographic, social and clinical characteristics of patients with AF in the
REMEDY study and in the GSH cohort.
3. To assess the frequency of CHADS2 and CHA2DS2VASc risk factors in the GSH cohort
and to calculate a CHADS2 and CHA2DS2VASc score on each of the patients with AF.
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4. To establish whether CHADS2 and CHA2DS2VASc scores further increase the risk of
stroke and death in this cohort of patients with valvular AF.
Methods 
This is a substudy of the Global Rheumatic Heart Disease Registry (the REMEDY study).  
We assessed those with AF from the entire cohort for prevalence and outcome data. Patients 
with ECG or Holter proven AF from the GSH cohort were further risk stratified using the 
CHADS2 and CHA2DS2Vasc scores. Clinical data was obtained from folder reviews and 
telephonic interviews. The CHADS2 and CHA2DS2Vasc scores for each patient in the GSH 
cohort were calculated. Patients were followed up for 2 years and information pertaining to 
death and stroke were obtained from folder reviews. These were then correlated with the 
CHADS2  and CHA2DS2Vasc scores. 
Results 
A total of 2624 REMEDY patients were analysed. Of these, 22% in the total cohort (586 of 
2684 patients) and 38.2% in the GSH cohort (187 of 489 patients) had AF. These patients 
were older (35 years vs. 25 years, p<0.0001), more likely to be female (73.1% vs. 65.6%, 
p=0.001) and more frequently had a history of congestive heart disease (41.0% vs. 33.3%, 
p=0.001) when compared to those in sinus rhythm. They also had significantly more strokes 
(13.8% vs. 5%, p<0.0001) and a poorer NYHA class (NYHA III& IV 30.8% vs. 25.2%, 
p=0.002). 
The cohort with AF had more severely impaired left ventricular (LV) function compared to 
those in sinus rhythm (Ejection fraction (EF) 57% vs. 61%. P<0.0001). The presence of a 
larger left atrial (LA) size, spontaneous echo contrast and LA thrombus was much greater in 
the AF cohort. Of those patients in AF, only 68% had received a prescription for warfarin. 
The GSH cohort was risk stratified using the CHADS2 and CHA2DS2VASc scores. Twenty- 
three percent of patients had a CHADS2 score of 0 and 27.7% of 1. When the same cohort 
was scored using the CHA2DS2VASc score, only 5.4% had a score of 0; this difference was 
mainly driven by the additional category of female gender. The patients in our cohort were 
young (median age 28 years) and had few comorbidities. Despite this, patients with AF did 
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significantly worse than those in sinus rhythm, with a stroke rate of 4.6% and a mortality rate 
of 13.1% observed at 2 years (compared to a 1.5% stroke rate and 5.5% mortality rate for 
those in sinus rhythm). The presence of any additional co-morbidities significantly reduced 
survival in both the short and long term. Greater CHA2DS2VASc score categories 






In a contemporary cohort of patients with rheumatic heart disease, AF is common with a 
prevalence of 22-39%. These patients were older and exhibited features of more advanced 
disease both clinically and on echo, compared to their sinus rhythm counterparts. The 
mortality and stroke rates in the AF group were high despite the relatively young age of this 
cohort. Mortality and stroke increased significantly and incrementally with each greater 
CHA2DS2VASc score category. Given the differences in chronicity between RHD in the 
developed world (i.e., disease of older people) and RHD in developing countries (i.e., disease 
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With a prevalence of 0.5% to 1% in the general population,1,2 atrial fibrillation (AF) is the 
most common cardiac arrhythmia. The incidence has risen to 5 million new cases per year.3 
Advancing age, essential hypertension, ischemic heart disease, heart failure and diabetes are 
conditions commonly associated with AF.4 Rheumatic heart disease is recognized as a 
common cause of AF. The prevalence of AF in rheumatic heart disease is around 20%.5,6 In 
more recent years, the literature has reported less frequently on valvular AF, but the problem 
persists in middle- and low socioeconomic countries where rheumatic heart disease remains 
prevalent.7  Furthermore, RHD in the developing world occurs in a much younger population 
when compared to the developed world. 
 
 
The presence of AF is associated with a significant risk of mortality and heart failure. The 
Framingham, Manitoba, Whitehall and Regional Heart Studies all showed a doubling in 
mortality when comparing patients with underlying heart disease in AF to those in sinus 
rhythm.8,9,10 In the Manitoba Follow-up study looking at the natural history of AF, the total 
mortality risk was increased 1.3 fold and the cardiovascular mortality (excluding fatal stroke) 
showed a relative risk of 1.37. 9 
 
 
AF is also the strongest independent predictor for stroke.4 It carries a 2 to 7 fold increased  
risk of ischemic stroke when compared to those patients without AF and one out of every six 
strokes are due to AF.9,10 The stroke risk however is heterogenous. Various risk factors 
interplay to create a variable risk of stroke and peripheral embolism. Though individuals 
essentially have identical underlying electrical disturbances in the atrium, the stroke risk in 
AF varies widely: from <1% to >20% per year.11 
 
 
Systemic embolism (especially in the form of stroke) is a serious and well-recognized 
complication of mitral valve disease. In 754 patients with chronic rheumatic heart disease 
followed up for 5833 patient-years, Szekely et al. showed an incidence of embolism of 1.5% 
per patient-year – it was however seven times higher in the group with AF compared to those 




The Framingham Heart Study analysed their cohort with rheumatic heart disease [RHD] and 
AF. A 17 fold increased stroke rate was noted when compared to age-matched controls,13
resulting in an attributable risk 5 times greater than in those with non-rheumatic AF.14 It is in 
light of this that anticoagulation is recommended for those with AF in the presence of 
valvular heart disease irrespective of other risk factors. 
The definition for valvular AF is however ambiguous. It is widely recognized that mitral 
stenosis is associated with an increased risk of thromboembolism.15,16 Of these patients with 
embolic phenomena in mitral stenosis, around 80% were in AF.17 There are conflicting 
theories  and  results  as  to  whether  or  not  mitral  regurgitation  increases  the  risk  of 
thromboembolism. No studies have shown aortic stenosis, aortic regurgitation or tricuspid 
regurgitation as a risk factor independent of AF for thromboembolism. This is thought to be 
on the basis that blood flow in the left atrium is not reduced.18
Mechanical valves show a definite increased risk of thromboembolic events of 4% per year if 
not on anticoagulation. Systemic embolism reduces to 0.7-1% per year on warfarin.19 Based 
on this information, a definition for valvular AF has been proposed: MARM-AF (Mechanical 
and Rheumatic AF). This specifies the disease entity, recognizing that only those patients 
with AF and specifically mitral stenosis and prosthetic valves are at increased risk of stroke – 
and thus clarifying management issues with regards to anticoagulation.18 This has been given 
consideration in the most recent ESC guidelines.20 Those with other valve lesions would be 
risk stratified using the scoring methods (as per non-valvular AF) referred to later in this text. 
No randomized trials looked at anticoagulation specifically in mitral stenosis, but 
observational retrospective studies showed a 4-15 fold reduction in events in those who 
received anticoagulation.21,22
Observational data in the 1970’s demonstrated the occurrence of embolic events in patients 
with AF due to heart disease other than mitral valve disease. Since then, the vast majority of 
studies on AF focused on those patients with non-valvular AF. Many risk factors for stroke 
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have been identified among patients with AF. The individual stroke risk depends on a 
combination of these risk factors. 
Risk factors that have consistently emerged as major independent predictors for stroke are: a 
history of previous stroke or TIA (RR 2.5), age (RR 1.5/decade), hypertension (RR 2.0) and 
diabetes (RR1.8).23,24 The Loire Valley AF project demonstrated the impact of age on stroke 
risk.25 A history of heart failure and female gender were also predictors in some other 
studies.26,27 Observational data showed an odds ratio of 1.81 for peripheral arterial disease 
predicting stroke.26
Over the years, many stroke risk prediction scores have been developed and divide patients 
into low-, moderate- or high-risk groups. Those with the highest risk for stroke were then 
eligible to receive oral anticoagulation (OAC) therapy. Numerous studies have shown that 
even those patients at moderate risk for stroke, do benefit from oral anticoagulation therapy, 
with dose-adjusted warfarin reducing the incidence of stroke in those with AF by more than 
60% when compared to placebo.28 Since OAC use is however associated with an increased 
risk of bleeding, especially intracranial bleeds, occurring at a rate of 2-5 per 1000 patients 
annually, 29 there has thus been a greater move to better risk stratify and identify those 
patients truly at low risk for stroke. In this low-risk patient group, the risks of oral 
anticoagulation likely outweigh the risk of thromboembolism.30,31
The CHADS2 score was derived from a combination of risk factors established in the AF 
Investigators (AFI)32 and the Stroke Prevention in Atrial Fibrillation (SPAF) cohorts.33 It 
allocated one point for each of the following – Congestive heart failure, Hypertension, Age 
75 or older, Diabetes mellitus, except 2 points for Stroke/TIA (Addendum 6,Table 1 in the 
Appendix- Section D). Low risk patients were defined as those having a score of 0, moderate 
risk was a score of 1-2 and high risk, a score of   >2. A strong correlation between the 
CHADS2 score and adjusted stroke rate emerged. Stroke rate per 100 patient years increases 
by a factor of 1.5 with each increase in score of 1 point.32
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There were a few limitations using the above model: having had a previous stroke or TIA 
only presumed a moderate risk (CHADS2 of 2), even though it was clear from previous 
studies that these patients were at highest risk of stroke recurrence. The risk score 
classification was revised, and now low risk = a score of 0, moderate risk = a score of 1 and 




But even those patients with moderate scores, i.e. CHADS2 scores of 1, had a significantly 
higher stroke rate compared to those with a CHADS2 score of 0; it thus classified many 
patients as having intermediate risk for stroke, even though some of them might be at truly 
low risk, with the risk of oral anticoagulation therefore outweighing the benefit and resulting 
in more people being anticoagulated than was justifiable. Conversely, among 25 286 Asian 
patients with a CHADS2 score of 0, the annual stroke rate ranged from 1.15% to 4.47%35. The 
same group of patients (CHADS2 0) was reclassified using the CHA2DS2VASc score- their 
scores now ranged from 0 to 3. There was a clear need to further risk stratify and identify 





The CHA2DS2VASC score aimed to address this need. – It utilizes the following variables: 
Congestive heart failure or LV dysfunction, Hypertension, Age 75 or older (2), Diabetes 
mellitus, Stroke/TIA(2), Vascular disease, Age 65-74, Female gender (Addendum 6,Table 2 
in the Appendix- Section D) to calculate a score. A score of 0=low risk, 1=intermediate risk 
and 2 or more=a high risk of stroke. 
 
 
This score was developed in 2010 and was better at predicting those patients who were truly 
at low risk for developing thromboembolism. It added 3 more factors – the 65-74 year old  
age group, female gender and vascular disease (in the form of a prior MI, peripheral arterial 
disease or aortic plaque). In the initial validation study, it only classified 9% as low risk (with 
no thromboembolic events occurring in this group). The same cohort classified according to 
the CHADS2 score had an event rate of 1.4%30. The added benefit of the CHA2DS2VASC 
score was also seen in a Danish cohort of 19 444 patients who had CHADS2 scores of 0.  
Their stroke rates ranged from 0.8% to 3.2% per year. The 28 132 patients who had a 
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CHADS2 score of 1 had stroke rates of up to 8.18% at 1 year 31. The CHA2DS2VASC score 
was particularly helpful in further delineating those patients with a CHADS2 score of 0 and 1 
- if the CHA2DS2VASC score was 0 in males or 1 in females (with female sex being the only 
risk factor), no oral anticoagulation was required. All other patients would therefore require 
oral anticoagulation 30. This is now the recommended risk scheme of choice by most 
guidelines societies 20,36. 
 
 
Neither of the 2 risk scores is foolproof, with c-statistics in the order of 0.69. 35 It also does  
not include more complex parameters such as renal impairment or AF burden, both of which 
have been shown to be associated with an increased risk of stroke. 37,38 However, both of 
these stroke-risk prediction scores have been widely used in studies to compare the newer  
oral anticoagulation drugs (NOACS) to the established treatment option (Vitamin K 
antagonists) in patients with non-valvular AF. These drugs trials have previously excluded 




Oral anticoagulation is advised in all patients with valvular AF. This group of patients has 
however not been studied in the contemporary era and little is known about the outcomes of 
stroke and mortality in valvular AF. Furthermore, the utilization of the CHADS2 and 
CHA2DS2VASC scores for the prediction of stroke in these patients has not been assessed 
and these scores may well be of incremental benefit in prognostication. This awareness of a 
more defined stroke and mortality risk in valvular AF patients will hopefully result in the 





Patients with rheumatic heart disease and atrial fibrillation have a significantly higher 
morbidity and mortality compared to those in sinus rhythm. The presence of other risk 
factors as described by the CHADS2 and CHA2DS2VASc scores significantly lead to an 




This is a substudy of the Global Rheumatic Heart Disease Registry (the REMEDY study). 
It aims to: 
1. Determine the prevalence of AF in the adult cohort of patients with rheumatic valvular
heart disease (RVHD).
2. Characterize the clinical and demographic profile of the patients with AF and RVHD.
3. Assess the frequency of CHADS2 (Congestive heart failure, Hypertension, Age 75 or
older, Diabetes Mellitus, Stroke/TIA(2)) and CHA2DS2VASc (Congestive heart failure,
Hypertension, Age 75 0r older (2), Diabetes mellitus, Stroke/TIA(2), Vascular disease, Age
65-74, Sex/gender- female) in the Groote Schuur Hospital (GSH) cohort of AF patients with
RVHD.
4. Characterize the outcomes in the form of stroke and death in this cohort of AF patients.
5. Assess whether there is an incremental increase in stroke risk and death with increasing
CHADS2 and CHA2DS2VASc scores.
Study Objectives 
The objectives of the study are to: 
1. Determine the prevalence of AF in the REMEDY study and in the GSH cohort.
2. Assess the demographic, social and clinical characteristics of patients with AF in the
REMEDY study and in the GSH cohort.
3. Assess the frequency of CHADS2 and CHA2DS2VASc risk factors in the GSH cohort and
to calculate a CHADS2 and CHA2DS2VASc score on each of the patients with AF.
4. Establish whether CHADS2 and CHA2DS2VASc scores further increase the risk of stroke
and death in this cohort of patients with valvular AF.
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Study Setting and design 
This cohort comprises patients already enrolled in the REMEDY study. REMEDY is a multi- 
center, international prospective registry collecting contemporary demographic and clinical 
data in patients with rheumatic heart disease. In total, 25 sites enrolled 3343 patients in 
Africa, the Middle East, Asia and South America with proven rheumatic heart disease. The 
design and rationale as well as the baseline findings for this study have been published 
previously 39,40. 
Patients with AF from the entire cohort will be assessed for prevalence and outcome data. In 
this cohort, the diagnosis of AF is made on clinical examination, and/or ECG and Holter 
monitoring. At the Groote Schuur Hospital site, only the patients with AF on ECG or Holter 
will be analysed and further risk stratified using the CHADS2 and CHA2DS2VASc scores. 
Groote Schuur Hospital is a tertiary center and one of two cardiology referral units in the 
Western Cape, South Africa. 
Patient Recruitment 
Inclusion criteria: 
• Patients with rheumatic heart disease who have ECG and/or Holter proven AF.
• Patients with another concomitant reason for oral anticoagulation (e.g.,
mechanical prosthetic valves) use will not be excluded from the study.
No distinction has been made between the various types of AF (paroxysmal vs. 
persistent vs. permanent). 
Exclusion from AF analysis: 
• Atrial flutter patients /other atrial arrhythmias
Data Collection: 
A standardised data collection form capturing all relevant demographic, clinical, ECG and 
echo  data  from  medical  charts  and  patient  interview  will  be  used.  (Baseline  CRF  – 
18
  
Addendum 2 – Section D). The ECG’s and Holter traces for each of the GSH patients would 
be reviewed by a cardiologist and the diagnosis of AF verified. 
 
 
An additional form capturing data pertaining to CHADS2 / CHA2DS2VASc risk factors will 
be filled using data from medical records or telephonic interviews.  (Addendum 3) 
• Congestive heart failure is defined as symptoms or clinical signs of heart failure. 
• Hypertension was defined by patient self-report, antihypertensive medications on 
prescription charts, and/or documented blood pressures of >140/90 mmHg. 
• Age: Two age categories were defined: 
1. Age 75 or older: In the CHADS2 score this scored one point; in the CHA2DS2VASc 
score, this scored 2 points 
2. Age 65-74: This age category did not apply to the CHADS2 score but scored 1 
point in the CHA2DS2VASc score 
• Diabetes mellitus was defined as self-reported, antiglycaemic medication (oral anti- 
glycaemics and insulin), random glucose of 11mmol/l or fasting glucose of 
6.7mmmol/l 
• Stroke/TIA was defined on the basis of self-reported symptoms or signs of a stroke or 
TIA or objective clinical or CT scan evidence of a stroke. 
• Vascular disease included those with a history of previous myocardial infarction or 
significant coronary disease on coronary angiography, peripheral vascular disease by 
symptoms, clinical signs or Doppler as well as proven aortic plaque on imaging (CT  
or MRI) 
The CHADS2 and CHA2DS2VASc scores for each patient with AF in the GSH cohort will be 
calculated and for each score, 3 categories will be considered: Low risk - score of 0, 
intermediate risk – score of 1 and high risk, score of 2 or more. 
 
 
Patients will be followed up and information pertaining to the outcomes of death and most 
importantly stroke will be captured from medical records and patient interviews in 
accordance with the REMEDY protocol. (Follow-up and Outcomes CRF’s – Addenda 4&5 – 





The prevalence of AF in the entire cohort of REMEDY patients and well as in the local 
Groote Schuur Hospital cohort will be calculated using the total REMEDY enrollments. 
(n=3343) and the total Groote Schuur enrolments (n=489) as denominators. These will be 
presented as percentages and as per 1000 population with 95% confidence intervals. 
Continuous variables will be expressed as means with standard deviations, or medians with 
interquartile ranges as appropriate. Categorical variables will be expressed as frequencies and 
percentages. Linear regression models will assess the relationship between the variables. Cox 
regression models will be used to assess the risk of stroke/thromboembolism using 
CHA2DS2VASc score. Kaplan-Meier estimates of event –free survival at 2 years will be 





Ethics approval has been granted for the REMEDY study. An ethics application for this 
substudy of REMEDY has been granted by the University of Cape Town Human Research 
Ethics Committee (HREC 127/2016 – Addendum 7 – Section D). The study will conform to 









Outputs / Dissemination of results 
 
This forms the basis of my M.Phil dissertation and will be submitted to a peer-reviewed 
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PART  B:  LITERATURE REVIEW 
 
Introduction 
Atrial fibrillation (AF) is the most common cardiac arrhythmia and remains a major 
contributor of cardio-embolic stroke and peripheral emboli. Although non-valvular AF 
becomes increasingly prevalent with advancing age, AF associated with valvular pathology 
affects a much younger age group. In this group, the presence of AF increases the risk of 
stroke up to 17-fold.1,2,3
In recent years, most stroke risk prediction tools focused on patients with non-valvular AF. 
Models such as the CHADS2 (Assigning one point for the variables of congestive heart 
failure, hypertension, age of 75 years or older, diabetes mellitus and 2 points for stroke or 
TIA) and CHA2DS2VASc (with the addition of a second age category – 64-74 scores one 
point, over 75 scores 2, as well as one point for female sex and peripheral artery disease) risk 
scores are commonly being used in clinical practice both to predict stroke risk as well as 
assessing the need for anticoagulation in non-valvular AF. 
The prevention of stroke with the use of anticoagulation treatment for AF has been evaluated 
in many randomized controlled trials and meta-analyses.4-17 Several guidelines have been 
developed in an attempt to standardize evidence-based practice and best ensure minimal risk 
of thrombo-embolism and bleeding in patients on anticoagulation therapy for AF.18,19,20
In the developing world, rheumatic heart disease remains common. AF in this group occurs in 
a much younger population but bears the same devastating consequences of increased stroke 
risk, morbidity and mortality. This group with valvular atrial fibrillation has not been 
extensively studied in the contemporary era. When RHD (and its related AF) does occur in 
the developed world, the patients tend to be older.
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This chapter will review: 
 
• The magnitude of the problem of AF 
• Stroke risk prediction in valvular AF 
• The changing definition of valvular AF 
• Stroke risk prediction in non-valvular AF 
• The utility of the risk prediction tools available for non-valvular AF, and 





A comprehensive literature search was performed using the following databases: MEDLINE, 
Google Scholar, Clinical Key, Clinical Evidence and Pubmed. The keywords that were used 
for the search were: atrial fibrillation, valvular atrial fibrillation, rheumatic atrial fibrillation, 
CHADS2, CHA2DS2VASc score, Anticoagulation for atrial fibrillation in CHADS2. This 
search yielded 72 references: 5 Guidelines, 43 observational/cohort studies, 5 review articles, 








AF is the most common cardiac arrhythmia and has a prevalence of about 0.5% - 1% in the 
general population.21,22 The incidence continues to rise with 5 million new cases reported per 
year. This is thought largely to be due to increased surveillance, better detection methods  
with more modern and accessible technologies, and improved survival.23,24 Prevalence 
increases with age, approaching 8% in those patients in the ninth decade.1,25,26 It is well 
known that advancing age, essential hypertension, ischemic heart disease, heart failure, 
diabetes and valvular heart disease are conditions commonly associated with AF.27 
 
 
Rheumatic heart disease (RHD) was previously recognized as a common cause of AF. In a 
cohort of 500 patients with mitral valve disease, Fleming et al found 57% of these patients 
(average age 50) to be in AF.2 Wipf et al. reported AF prevalence rates in a surgical series of 
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rheumatic heart disease of up to 75%.28 Diker et al. found a 39% prevalence of AF in a cohort 
of 1110 patients with rheumatic heart disease. Of those with pure mitral stenosis (854 
patients), 403 (47%) had AF, accounting for 29% of the total cohort. Patients with the 
combined lesions of mitral stenosis and regurgitation and tricuspid regurgitation lesions had 
even higher rates of AF (70%) in this cohort.3 
 
 
Though other studies showed slightly lower rates, the prevalence of AF in rheumatic heart 
disease is consistently about 20%.29,30 Although more recent literature reports less frequently 
on valvular AF, the problem persists in middle- and low socio-economic countries where 
rheumatic heart disease remains prevalent.31 
 
 
The presence of AF is associated with a significant risk of mortality and heart failure. The 
Framingham, Manitoba, Whitehall and Regional Heart Studies all showed a doubling in 
mortality when comparing patients with underlying heart disease in AF to those in sinus 
rhythm.32,33,25 In the Manitoba Follow-up study looking at the natural history of AF, the total 
mortality risk was increased 1.3 fold and the cardiovascular mortality (excluding fatal stroke) 
showed a relative risk of 1.37.33 It is also the strongest independent predictor for stroke.4 
 
 
Patients with AF have a 2 to 7 fold increased risk of ischemic stroke compared to those 
without AF and one out of every six strokes are due to AF.1,4,25,33 The stroke risk is 
heterogenous – a number of mechanisms relating to Virchow’s triad of thrombogenesis are at 
play: 1. Flow disturbance due to stasis in the left atrium (abnormal blood flow), 2. Structural 
heart and/or vascular disease (representing the abnormal ‘vessel wall’), 3. Abnormal 
coagulation both in the form of reduced platelet survival and increased platelet stickiness. 
(this has been studied extensively in recent years).34,35,36 Numerous risk factors interplay to 
create a variable risk of stroke and peripheral embolism. Although individuals essentially 
have identical underlying electrical disturbances in the atrium, the stroke risk in AF varies 
widely: from <1% to >20% per year.37 
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Systemic embolism is a serious and well-recognized complication of mitral valve disease. 
Strokes account for more than 60% of these embolic events.38,2 Szekely et al. showed an 
incidence of embolism of 1.5% per patient-year when following up 754 patients with chronic 
rheumatic heart disease for 5833 patient-years. This was seven times higher in the group with 
AF compared to those in sinus rhythm (5% per patient year in AF compared to 0.7% per 
patient year in sinus rhythm).39 
 
 
A comprehensive study of 839 cases showed a four-fold increase in the incidence of embolic 
phenomena in those patients with AF compared to those in sinus rhythm. In both groups, 
there was an increase in events with increasing age.40 
 
 
Fleming et al in 1971 showed that in a cohort of 500 inpatients in Cambridge UK, 57% of 
patients were found to be in AF. Of those in AF, 35% presented with embolic phenomena. 
The incidence of embolic events once again increased with age. The severity of the mitral 
valve disease did not influence the incidence of embolic events.2 
 
 
In the Framingham Heart Study, patients with (RHD) and AF had a 17 fold increased stroke 
rate compared to age-matched controls41, with an attributable risk 5 times greater than those 
with non-rheumatic AF.1 It is in light of this that anticoagulation is recommended for those 








The definition for valvular AF is ambiguous. It is widely recognized that mitral stenosis is 
associated with an increased risk of thromboembolism.42,43 However, it remains unclear 




mitral stenosis who have an embolic event, +/- 80% are in atrial fibrillation.44 If a previous 
event has occurred, there is a very high recurrence rate of 15-40 events per 100 patient 
months.45,46
There are conflicting theories and results as to whether or not mitral regurgitation increases 
the risk of thromboembolism. A retrospective study showed that thromboembolism rates 
were similar when compared to those with no mitral regurgitation.47 Due to the higher blood 
flow patterns in the atria, it was actually thought by some to be protective. In mitral valve 
prolapse, some series showed an increase in the rate of thromboembolism but this was not 
reproduced in the later Framingham study.48 No studies have shown aortic stenosis, aortic 
regurgitation or tricuspid regurgitation as a risk factor independent of atrial fibrillation for 
thromboembolism. This is thought to be on the basis that blood flow in the left atrium is not 
reduced.46 Mechanical valves show a definite increased risk of thromboembolic events of 4% 
per year if not on anticoagulation. Systemic embolism reduces to 0.7-1% per year on 
warfarin.49
Based on this information, a more descript definition for valvular AF has been proposed: 
MARM-AF (Mechanical and Rheumatic AF). This specifies the disease entity more clearly, 
rand recognizes that only those patients with AF and specifically mitral stenosis and 
prosthetic valves are at increased risk of stroke – thus clarifying management issues with 
regards to anticoagulation.46 This has been given consideration in the most recent ESC 
guidelines.19 Those with other valve lesions would be risk stratified using the scoring  
methods referred to later in this text. 
No randomized trials looked at anticoagulation specifically in mitral stenosis, but 
observational retrospective studies showed a 4-15 fold reduction in events in those who 
received anticoagulation.45,50 Numerous observational studies in valvular AF suggested long 
term anticoagulation as a method of preventing systemic emboli.51,52,38 Roy et al. reviewed 
254 patients with AF to assess the incidence of embolic events relative to the type of 
cardiovascular disease and anticoagulant use. Thirty-two events occurred during an 833 
patient   year   follow-up.   Thirty   events   occurred   in   the   549   patient   years   with   no 
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anticoagulation therapy (5.46 per 100 patient years) and only two events occurred in those on 
anticoagulation, during a 284 patient year period (0.7 per 100 patient years), demonstrating 
an 8-fold increase in frequency. This observation was regardless of the presence of mitral 
disease or whether the AF was chronic or paroxysmal. This suggested that anticoagulation  in 
AF patients should not be limited only to those with mitral valve disease53 and that other  risk 








Observational data in the 1970’s suggested the occurence of embolic events in patients with 
AF due to heart disease other than mitral valve disease. A necropsy study of 333 patients with 
AF showed embolism to occur in 41 % of patients with mitral valve disease, 35% of those 
with ischemic heart disease and 17% of those with ‘other’ heart disease.54 
 
 
Since then, the vast majority of studies on AF focused on those patients with non-valvular 
AF. Many risk factors for stroke have been identified among patients with AF. The individual 
stroke risk depends on a combination of these risk factors. Risk factors that have consistently 
emerged as major independent predictors for stroke are: a history of previous stroke or TIA 
(RR 2.5), age (RR 1.5/decade), hypertension (RR 2.0) and diabetes (RR1.8).18,55 The Loire 
Valley AF project demonstrated the impact of age on stroke risk.56 A history of heart failure 
and female gender were also predictors in some other studies.57,58 Observational data showed 
an odds ratio of 1.81 for peripheral arterial disease predicting stroke.56 
 
 
Over the years, many stroke risk prediction scores have been developed. These are used to 
categorize patients into a low-, moderate- or high-risk groups with the aim of anticoagulating 
those patients at highest risk for stroke. Numerous studies have shown that even those 
patients at moderate risk for stroke, do benefit from oral anticoagulation therapy, with dose- 
adjusted warfarin reducing the incidence of stroke in those with AF by more than 60% when 
compared to placebo.59 Since it’s use is however associated with an increased risk on 
bleeding, especially intracranial  bleeds,  occurring  at  a  rate  of  2-5  per  1000  patients 
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annually.60 There has thus been a greater move to better risk stratify and identify those 
patients truly at low risk for stroke who would not require oral anticoagulation.61,62 
 
 




CHADS2 score – Congestive heart failure, Hypertension, Age 75 or older, Diabetes mellitus, 




For each risk factor that the patient has, they score one point except for stroke or TIA which 
scores 2 points. The CHADS2 score was derived from a combination of risk factors 
established in the AF Investigators (AFI)4 and the Stroke Prevention in Atrial Fibrillation 
(SPAF)15 studies and has been in use since 2001. The initial validation of the CHADS2 score 
was in the National Registry of Atrial Fibrillation (NRAF)63 in 1733 patients who had 
non-valvular AF and not taking oral anticoagulation at discharge. In this cohort, low risk 
patients were defined as those having a score of 0, moderate risk was a score of 1-2 and high 
risk, a score of >2. A strong correlation between the CHADS2 score and adjusted stroke rate 
emerged. Stroke rate per 100 patient years increases by a factor of 1.5 with each increase in 




There were a few limitations using the above model: having had a previous stroke or TIA 
only presumed a moderate risk (CHADS2 of 2), even though it was clear from previous 
studies that these patients were at highest risk of stroke recurrence. The risk score 
classification was revised, and now low risk = a score of 0, moderate risk = a score of 1 and 




It was noted however, that even those with moderate scores, i.e. CHADS2 scores of 1, had a 
significantly  higher  stroke  rate  compared  to  those  with  a  CHADS2  score  of  0;  it  thus 
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classified many patients as having intermediate risk for stroke, even though some of them 
might be at truly low risk, with the risk of oral anticoagulation therefore outweighing the 
benefit and resulting in more people being anticoagulated as was necessary. Conversely, 
among 25 286 Asian patients with a CHADS2 score of 0, annual stroke rate of 1.15% to 
4.47 %.65 Their CHA2DS2VASc score ranged from 0 to 3. The need arose to risk stratify these 
patients further and to identify those who were truly at low risk (and thus not requiring 
anticoagulation). 
The CHA2DS2VASC score uses the following variables: – Congestive heart failure or LV 
dysfunction, Hypertension, Age 75 or older (2), Diabetes mellitus, Stroke/TIA(2), Vascular 
disease, Age 65-74, Female gender (Addendum 6,Table 2 in the Appendix- Section D) A 
score of 0=low risk, 1=intermediate risk and 2 or more=high risk of stroke. 
This score was developed in 2010 and was better at predicting those patients who were truly 
at low risk for developing thromboembolism. It added 3 more factors – the 65-74 year old  
age group, female gender and vascular disease (in the form of a prior MI, peripheral arterial 
disease or aortic plaque). In the initial validation study, it only classified 9% as low risk (with 
no thromboembolic events occurring in this group). The same cohort classified according to 
the CHADS2 score had an event rate of 1.4%.61 The added benefit of the CHA2DS2VASC 
score was also seen in a Danish cohort of 19 444 patients who had CHADS2 scores of 0.  
Their stroke rates ranged from 0.8% to 3.2% per year. The 28 132 patients who had a 
CHADS2 score of 1 had stroke rates of up to 8.18% at 1 year.62 The CHA2DS2VASC score 
was particularly helpful in further delineating those patients with a CHADS2 score of 0 and 1 
- if the CHA2DS2VASC score was 0 in males or 1 in females (with female sex being the only
risk factor), no oral anticoagulation was required. All other patients would therefore require
oral anticoagulation.61 This is now the recommended risk scheme of choice suggested by
most guidelines and cardiology societies.19,20
Neither of the 2 risk scores are fool-proof with c-statistics in the order of 0.69.65 It also does 
not include more complex parameters such as renal impairment or AF burden that have been 
shown to be associated with an increased risk of stroke.66,67
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Risk factor prediction tools in valvular AF 
Both of these stroke-risk prediction scores have been widely used in studies to compare the 
newer oral anticoagulation drugs (NOACS) to the established treatment option (Vitamin K 
antagonists) in patients with non-valvular AF. These drugs trials have previously excluded 
patients with valvular AF. 
Conclusion 
Oral anticoagulation is advised in all patients with valvular AF. This group of patients has 
however not been studied in the contemporary era and little is known about the outcomes of 
stroke and mortality. Furthermore, the utilization of the CHADS2 and CHA2DS2VASC scores 
for the prediction of stroke in these patients has not been assessed and these scores may well 
be of incremental benefit in prognostication. This awareness of a more defined stroke risk in 








1. Wolf PA, Abbott RD, Kannel WB. Atrial Fibrillation as an independent risk factor for 
stroke: the Framingham Study. Stroke 1991; 22(8) 983-988. 
2. Fleming HA, Bailey S. Mitral valve disease, systemic embolism and anticoagulants. 
Postgraduate Medical Journal 1971; 47: 599-604 
3. Diker E, Aydogdy S, Ozdemir M, Kural T et al. Prevalence and Predictors of Atrial 
Fibrillation in Rheumatic Valvular Heart Disease. Am J Cardio 1996; 77: 96-98. 
4. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic 
therapy in atrial fibrillation. Analysis of pooled data from five randomised controlled 
trials. Arch Intern Med 1994; 154: 1449-1457. 
5. Hart RG, Benavente O, McBride R et al. Antithrombotic therapy to prevent stroke in 
patients with Atrial Fibrillation: a meta-analysis. Ann Intern Med 1999; 131: 492-501. 
6. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect 
of low-dose warfarin on the risk of stroke in patients with non-rheumatic atrial 
fibrillation. N Engl J Med 1990; 323: 1505-1511 
7. EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non- 
rheumatic atrial fibrillation after transient ischemic attack or minor stroke. Lancet 
1993; 342: 1255-1262. 
8. Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for 
prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial 
Fibrillation II Study. Lancet 1994; 343: 687-691. 
9. Stroke Prevention in Atrial Fibrillation Investigators. Adjusted dose warfarin versus 
low-intensity, fixed dose warfarin plus aspirin for high-risk patients with atrial 
fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 
1996; 348: 633-688. 
10. Petersen P, Boysen G, Godtfredsen J et al. Placebo-controlled, randomised trial of 
warfarin and aspirin for prevention of thromboembolic complications in chronic atrial 
fibrillation. The Copenhagen AFASAK study. Lancet 1989; 1: 175-179. 
11. Pengo V, Zasso A, Barbero F et al. Effectiveness of fixed minidose warfarin in the 
prevention of thromboembolism and vascular death in non-rheumatic atrial fibrillation. 
Am J Cardiol 1998; 82: 433-437. 
35
  
12. Gullov AL, Koefoed BG, Petersen P et al. Fixed minidose warfarin and aspirin alone 
and in combination vs adjusted dose warfarin for stroke prevention in atrial  
fibrillation: Second Copenhagen Atrial Fibrillation, Aspirin and Anticoagulation  
Study. Arch Intern Med 1998; 158: 1513-1521. 
13. Ezekowitz MD, Bridgers SL, James KE et al. Warfarin in the prevention of stroke 
associated with non-rheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in 
Nonrheumatic Atrial Fibrillation Investigators. N Engl J Med 1992; 327: 1406-1412. 
14. Connolly SJ, Laupacis A, Gent M et al. Canadian Atrial Fibrillation Anticoagulation 
(CAFA) study. J Am Coll Cardiol 1991; 18: 349-355. 
15. Stroke Prevention in Atrial Fibrillation Study. Final results. Circulation 1991; 84: 527- 
539. 
16. Hellemons BS, Langenberg M, Lodder J et al. Primary prevention of arterial 
thromboembolism in non-rheumatic atrial fibrillation in primary care: randomised 
controlled trial comparing two intensities of coumarin with aspirin. BMJ 1999; 319: 
958-964. 
17. Yamaguchi T. Optimal intensity of warfarin therapy for secondary prevention  of 
stroke in patients with nonvalvular atrial fibrillation: a multicentre, prospective 
randomized trial. Japanese Nonvalvular Atrial Fibrillation-Embolism Secondary 
Prevention Cooperative Study Group. Stroke 2000; 31: 817-821. 
18. National Institute for Health and Care Excellence. Atrial Fibrillation: the management 
of atrial fibrillation. http://guidance.nice.org.uk/CG180. Published June 2014. 
Accessed June 18,2014. 
19. Kirchhof P, et al. 2016 ESC Guidelines for the management of atrial fibrillation 
developed in collaboration with EACTS. European Heart Journal 2016 ; 37:2893- 
2962 
20. January CT, Wann LS, Alpert JS, et al. American College of Cardiology/ American 
Heart Association Task Force on Practice Guidelines. 2014 AHA/ACC/HRS guideline 
for the management of patients with atrial fibrillation: a report of the  American 
College of Cardiology/ American Heart Association Task Force on Practice Guidelines 
and the Heart Rhythm Society. Journal of the American College of Cardiology 2014; 
64(21):e1-e76. 
21. Go AS, Hylek EM, Phillips KA et al. Prevalence of diagnosed atrial fibrillation in 
adults:  national  implications  for  rhythm  management  and  stroke  prevention:  the 
  
AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001; 
285: 2370-2375. 
22. Feinberg WM, Blackshear JL, Laupacis A, et al. Prevalence, age distribution, and 
gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med 
1995; 155: 469-473. 
23. Chugh SS, Harmceller R, Narayan K, Singh D, Rienstra M, Benjamin EJ et al. 
Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. 
Circulation 2014;129: 837-847 
24. Schnabel R, Yin X, Gona P, Larson M, Beiser A, McManus D, et al. 50 Year trends in 
atrial fibrillation prevalence, incidence, risk factors, and mortality in Framingham 
Heart Study: a cohort study. Lancet 2015; 386: 154-62.) 
25. Flegel KM, Shipley MJ, Rose G. Risk of stroke in non-rheumatic atrial fibrillation 
[published erratum appears in Lancet 1987; 1: 878]. Lancet 1987; 1: 526-529. 
26. Furberg CD, Psaty BM, Manolio TA, et al. Prevalence of atrial fibrillation in elderly 
subjects (the Cardiovascular Health Study). Am J Cardiol 1994; 74: 236-241. 
27. Stevenson WG, Stevenson LW, Middlekauff HR, et al. Improving survival for patients 
with atrial fibrillation and advanced heart failure [published erratum appears in J Am 
Coll Cardiol 1997; 30: 1902] J Am Coll Cardiol 1996; 28: 1458-1463. 
28. Wipf JE, Lipsky BA. Atrial Fibrillation. Thromboembolic risk and indications for 
anticoagulation. Arch Intern Med 1990; 150: 1598-1603 
29. Bentivoglio LG, Uricchio JF, Waldo A et al. An electrocardiographic analysis of sixty 
five cases of mitral regurgitation. Circulation 1958; 18: 572. 
30. Probst P, Goldschlager N, Selzer A. Left atrial size and the risk of stroke and death. 
The Framingham Heart Study. Circulation 1995; 92: 835. 
31. Sliwa K, et al. Spectrum of Heart disease and risk factors in a black urban population 
in South Africa (the Heart of Soweto Study): a cohort study. Lancet 2008; 371: 915- 
922 
32. Kannel WB, Abbott RD, Savage DD et al. Coronary heart disease and atrial 
fibrillation: the Framingham Study. Am Heart J 1983; 106: 389-396. 
33. Krahn AD, Manfreda J, Tate RB et al. The natural history of atrial fibrillation: 
incidence, risk factors, and prognosis in the Manitoba Follow-up Study. Am J Med 
1995; 98: 476-84. 
34. Watson T, Shantsila E, Lip GY. Mechanisms of thrombogenesis in AF: Virchow’s 
triad revisited. Lancet 2009; 373 (9658): 155-166. 
37
 
35. Steele PP, Weily HS, Davies H, Genton E. Platelet survival in patients with rheumatic
heart disease. New England Journal of Medicine 1974; 290: 537-539.
36. Toy JL, Lederer DA, Tulpule AT, Tandon AP, Taylor SH, McNicol GP. Coagulation
studies in rheumatic heart disease. British Heart Journal 1980;43: 301-305.
37. Olesen JB, Lip GY, Hansen PR, Tolstrup JS, Lindhardsen J, Selmer C, Ahlehoff O,
Olsen AM, Gislason GH, Torp-Pedersen C. Validation of risk stratification schemes
for predicting stroke and thromboembolism in patients with atrial fibrillation: a
nationwide cohort study. Br Med J 2011;342:d124
38. Wood PH. An Appreciation of mitral stenosis Part I: Clinical features. British Medical
Journal 1954;1: 1051.
39. Szekely P. Systemic Embolism and Anticoagulant Prophylaxis in Rheumatic Heart
Disease. BMJ 1964; 1: 1209-1212.
40. Coulshed N, Epstein EJ, McKendrick CS, Galloway RW, Walker E. Systemic
embolism in mitral valve disease. British Heart Journal 1970;32:26-34.
41. Wolf PA, Dawber TR, Thomas HE Jr et al. Epidemiologic assessment of chronic
atrial fibrillation and risk of stroke: the Framingham study. Neurology 1978; 28: 973-
977.
42. Rowe JC, Bland EF, Sprague HB, White PD. The course of mitral stenosis without
surgery: ten-and twenty year perspectives. Ann Intern Med 1960;52:741-749.
43. Caplan LR, D’Cruz I, Hier DB, Reddy H, Shah S. Atrial size, atrial fibrillation, and
stroke. Ann Neurol 1986;19:158-161.
44. Olesen KH. The natural history of 271 patients with mitral stenosis under medical
treatment.  Br H J 1962; 24: 349-357
45. Laupacis A, Albers G, Dunn M, Feinberg W. Antithrombotic therapy in Atrial
Fibrillation. Chest 1992;102: 4265-4335.
46. De  Caterina  R,  Camm  AJ.  What  is  ‘valvular’  atrial  fibrillation?  A  reappraisal.
European Heart Journal 2014;35: 3328-3335.
47. Wada Y, Mizushige K, Ohmori K, Iwado Y, Kohno M, Matsuo H. Prevention of
cerebral thromboembolism by low-dose anticoagulant therapy in atrial fibrillation with
mitral regurgitation. J Cardiovasc Pharmacol 2001;37:422-426
48. Freed LA, Levy D, Levine RA, Larson MG, Evans JC, Fuller DL, Lehman B,
Benjamin EJ. Prevalence and clinical outcome of mitral valve prolapse. N Eng J Med
1999;341: 1-7.
49. Cannegieter SC, Rosendaal FR, Briet E. Thromboembolic and bleeding complications
38
 
in patients with mechanical heart valve prostheses. Circulation 1994;89: 635-641. 
50. Abernathy  WS,  Willis  PW  3rd.  Thromboembolic  complications  of  rheumatic heart
disease. Cardiovasc Clin 1973;5: 131-175.
51. Owren PA. The results of anticoagulation therapy in Norway. Archives if Internal
Medicine 1963;110:240.
52. Casella L, Abelmann WH, Ellis LB. Patients with mitral stenosis and systemic emboli:
Hemodynamic and clinical observations. Archives of Internal Medicine 1964;114: 773
53. Roy D, Marchand E, Gagne P, Chabot M, Carter R. Usefulness of anticoagulation
therapy in the prevention of embolic complications of AF. American Heart Journal
1986;112(5) 1039-1043.
54. Hinton RC, Kistler JP, Fallon JT, Friedlich AL, Fisher CM. Influence of aetiology of
AF on incidence of systemic embolism. American Journal of Cardiology 1977;40(4)
509-513.
55. Hart RG, Pearce LA, McBride R, et al. the Stroke Prevention in Atrial Fibrillation
(SPAF) Investigators. Factors associated with ischemic stroke during aspirin therapy
in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials.
Stroke 1999;30: 1223-1229.
56. Olesen JB, Fauchier L, Lane DA, Taillandier S, Lip GY. Risk factors for stroke and
thromboembolism in relation to age among patients with atrial fibrillation: the Loire
Valley Atrial Fibrillation Project. Chest 2012; 141(1):147-153.
57. Pisters R, Lane DA, Marin F, et al. Stroke and thromboembolism in atrial  fibrillation.
Circ J. 2012; 76:2289-2304.
58. Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for
ischemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish
Atrial Fibrillation cohort study. European Heart Journal 2012; 33: 1500-1510.
59. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic treatment to prevent
stroke in patients who have non-valvular AF. Ann Intern Med 2007:146: 857-867.
60. van Walraven C, Hart RG, Singer DE, et al. Oral anticoagulants vs aspirin in non- 
valvular atrial fibrillation: an individual patient meta-analysis. J Am Med Assoc
2002:288: 2441-2448.
61. Lip GY, Nieuwlaat R, Pisters R et al. Refining clinical risk stratification for predicting
stroke and thromboembolism in atrial fibrillation using a novel risk factor-based
39
 
approach: the Euro Heart Survey on Atrial Fibrillation. Chest 2010; 137:263-272. 
62. Olesen JB, Torp-Pedersen C, Hansen ML, et al. The value of the CHA2DS2VASC
score for refining stroke risk stratification in patients with atrial fibrillation with a
CHADS2 score 0-1: a nationwide cohort study. Thromb Haemost 202;107:1172-1179.
63. Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification
schemes for predicting stroke: results from the National Registry of Atrial Fibrillation.
JAMA 2001;285:2864-2870
64. Lip G. Can we predict stroke in Atrial Fibrillation? Clinical Cardiology 2012; 35 (S1):
21-27
65. Chao TF, Liu CJ, Tuan TC et al. Comparisons of CHADS2 and CHA2DS2-Vasc scores
for stroke risk stratification. Heart Rhythm 2016;13: 46-53
66. Olessen JB, Lip GY, Kamper AL, Hammel K, Kober L, Lane DA, Lindhardssen J,
Gislasen GH, Torp-Pedersen C. Stroke and bleeding in atrial fibrillation with chronic
kidney disease. N Eng J Med 2012; 367:625-635.
67. Glotzer TV, Daoud EG, Wyse DG, Singer DE, Ezekowitz MD, Hilkler CM, Claton
QD, Ziegler PD. The relationship between daily tachyarrhythmia burden
from implantable device diagnostics and stroke risk: the TREDIDS Study. Circ
Arrythm Electrophysiol 2009;2: 474-480.
68. Karthikeyan G, Zuhlke L, et al. Rationale and design of a Global Rheumatic
Heart Disease Registry: the REMEDY Study. American Heart Journal 2012;
163 (4) 535-540
69. Zuhlke L, Engel M, et al. Characteristics, complications, and gaps in
evidence-based interventions in rheumatic heart disease: the Global
Rheumatic Heart Disease Registry (the REMEDY study). European Heart
Journal 2015; 36 (18):1115-1122.
70. Hart RG. Atrial Fibrillation and Stroke Prevention. N Engl J Med 2003; 349(11): 1015-
1016.
71. Wessler S, Gitel S. Seminars in Medicine of the Beth Israel Hospital, Boston:
Warfarin: From bedside to bench. New Engl J Med 1984; 311(10): 645-652.
72. Fuster V, Ryden L, Cannom D et al. ACC/AHA/ESC Guidelines for the management
      of patients with atrial fibrillation: executive summary Report 
73. Whitlock RP, Sun JC, Fremes SE, et al. Antithrombotic and thrombolytic therapy for
valvular disease: Antithrombotic therapy and Prevention of thrombosis, 9th ed:
40 
  
       American College of Chest Physicians Evidence-based Clinical Practice Guidelines.  
       Chest 2012; 141(2): e576S-e600S. 
72. You JJ, Singer DE, Howard PA, et al. Antithrombotic therapy for Atrial 
Fibrillation: Antithrombotic Therapy and Prevention of thrombosis, 9th ed: 
American College of Chest Physicians Evidence-based Clinical Practice 













Prevalence, characteristics and additional stroke risk stratification: An analysis of the 




Blanche J Cupido 
 












Atrial fibrillation (AF) is the most common arrhythmia and may be complicated by embolic 
stroke or peripheral emboli. In addition, it is associated with a significant risk of mortality 
and heart failure. 
 
Rheumatic heart disease (RHD) remains a major problem in the developing world. Systemic 
embolism (of which 60% are due to strokes)1 is a well recognized complication of mitral 
valve disease. In this population, the AF prevalence was previously described to be around 
20% . It occurs in a much younger age group, even when compared to RHD patients in the 
developed world2 In the Framingham study there was a 17 fold increase in the stroke rate 
compared to age matched controls.3 
 
There has been much debate in the definition of valvular AF. It is widely recognized and 
accepted that mitral stenosis (MS) is associated with an increased risk of thromboembolism4, 
but it is unclear if the pathogenesis is identical to that of non-valvular AF. In those patients 
with MS, and a previous ischemic cerebral event, the rate of recurrence is high. The studies 
showing increased stroke rates in mitral regurgitation are conflicting5, and no studies have 
shown an increased stroke risk in other native valve lesions. Mechanical valves are associated 
with a definite increased risk of thromboembolic events.6 There are no randomized trials 
examining the effectiveness of anticoagulation specifically in mitral stenosis. Observational 
studies utilizing warfarin as an anticoagulant show a reduced embolic event rate.7 
 
Over time, many additional risk factors for stroke have been identified. Those that have 
consistently emerged as independent risk factors were: a history of previous stroke or TIA, 
age, hypertension and diabetes.8 A few other studies also implicated female gender and 
congestive heart failure.9 With the decline of RHD in the developed world and the increasing 
conglomerate of risk factors in the setting of non-valvular AF, stroke risk stratification tools 
such as the CHADS210 (Congestive heart failure, hypertension, age of 75 or older, diabetes 
mellitus or stroke/TIA) or CHA2DS2VASc11 (with the addition of a second age category, 
female gender, and peripheral artery disease) scores have been developed. These are 
increasingly being utilized to determine the need for anticoagulation, and are now 
recommended by major cardiac society guidelines.12,13 Their main value lies in identifying 
those patients who are at sufficient risk for stroke, where the benefit of using  anticoagulation 
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would outweigh the risk of bleeding. Stroke prevention with the use of anticoagulation 
(mainly Vitamin K antagonists, and now, in recent times also NOACS) for those who score 2 
or more on the above risk scores, have been evaluated in randomized  controlled trials. 
Patients with valvular AF have traditionally been excluded from these studies since they were 
already deemed to be an extremely high risk group. 
Valvular AF has not been extensively studied in the contemporary era. Older data suggested 
that oral anticoagulation is advised in all patients with valvular AF – mainly based on the 
observational studies showing up to a 17 fold risk.1 This group of patients has however not 
been studied in the contemporary era and very little is known about the outcomes of stroke 
and mortality in this cohort. The utilization of the CHADS2 and CHA2DS2VASc scores for  
the prediction of stroke has not been assessed and these scores may well provide incremental 
benefit in prognostication and resultantly, more diligent prescription and monitoring of 
anticoagulation, and consequently improved outcomes. 
The objectives of this study were as follows - 
1. To determine the prevalence of AF in the REMEDY study and in the GSH cohort.
2. To assess the demographic, social and clinical characteristics of patients with AF in the
REMEDY study and in the GSH cohort.
3. To assess the frequency of CHADS2 and CHA2DS2VASc risk factors in the GSH cohort
and to calculate a CHADS2 and CHA2DS2VASc score on each of the patients with AF.
4. To determine whether CHADS2 and CHA2DS2VASc scores further increase the risk of







The participants were patients already enrolled in the REMEDY study.14 This is a  
multicentre, international registry collecting contemporary demographic and clinical data in 
patients with rheumatic heart disease. In total, 3343 patients were enrolled in 25 sites in 
Africa, India and Yemen.15 In this sub-study, we assessed those with AF from the entire 
cohort for prevalence and outcome data. Patients with Atrial flutter/other arrhythmias were 
excluded. The patients with ECG or Holter proven AF from the Groote Schuur Hospital site 
were analysed and further risk stratified using the CHADS2 and CHA2DS2VASc scores. 
Groote Schuur Hospital is a tertiary care centre in Cape Town, South Africa and one of two 
cardiology referral units in the Western Cape. It provides general cardiology care to the 
Western and Southern Cape Province. All subjects had given written informed consent to 
participate in the study. Ethics approval for this substudy was granted by the University of 




Study data collection 
 
A standardized data collection form was used to capture relevant demographic, clinical, ECG 
and echocardiography data from both patient interviews and medical charts/records. For the 
entire REMEDY cohort, the diagnosis of AF was clinical and/or on ECG and Holter. The 
ECG’s and Holter traces for each of the GSH patients was reviewed by a cardiologist, the 
diagnosis of AF verified and only those with ECG and Holter proven AF included. An 
additional form was utilized to capture other AF risk factors to determine a CHADS2 and 
CHA2DS2VASc score for each patient. Additional information was obtained from hospital 
charts and occasionally telephonic interviews. 
Congestive heart failure is defined as symptoms or clinical signs of heart failure. 
Hypertension was defined patient self-reporting, antihypertensive medications on prescription 
charts, documented blood pressures of >140/90. 
Two age categories were defined as age 75 or older: In the CHADS2 score this scored one 
point; in the CHA2DS2VASc score, this scored 2 points. The age 64-75 category did not 
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apply to the CHADS2 score but scored 1 point in the CHA2DS2VASc score. Diabetes mellitus 
was defined as self-reported, antiglycaemic medication (oral anti-glycaemics and insulin), 
random glucose of 11mmol/l or fasting glucose of 6.7mmmol/l. Stroke/TIA was defined on 
the basis of self-reported symptoms or signs of a stroke or TIA or objective clinical or CT 
scan evidence of a stroke. Vascular disease included those with a history of previous 
myocardial infarction or significant coronary disease on coronary angiography, peripheral 
vascular disease by symptoms, clinical signs or Doppler as well as proven aortic plaque on 
imaging (CT or MRI). 
 
The CHADS2 and CHA2DS2VASc scores for each patient with AF in the GSH cohort was 
calculated and for each score, 3 categories will be considered: Low risk - score of 0, 
intermediate risk – score of 1 and high risk, score of 2 or more. 
 
 
Patients were followed up annually for a 2-year period. Information pertaining to the 
outcomes of death and most importantly stroke was captured from medical records and 
patient interviews in accordance with the REMEDY protocol. These outcomes were 





The prevalence of AF in the entire cohort of REMEDY patients and well as in the local GSH 
cohort was calculated using the total REMEDY enrollments (n=3343) and the total Groote 
Schuur enrolments (n=489) as denominators. These are presented as percentages. The clinical 
characteristics of the AF cohort were compared to those patients in sinus rhythm. Continuous 
variables are expressed as means with standard deviations, or medians with interquartile 
ranges as appropriate. Categorical variables are expressed as frequencies and percentages. 
Linear regression models assessed the relationship between the variables. Cox regression 
models are used to assess the risk of stroke/thromboembolism using CHA2DS2VASc score. 
Kaplan-Meier estimates of event –free survival at 2 years were obtained, relating it to the 




A total of 3343 patients were enrolled in REMEDY but only 2624 patients reported detailed 
ECG findings. Of the 2624 patients with full ECG information, 586 (22.3%) had AF. (Fig 1) 
Within the GSH cohort, the prevalence of AF was 38.2%. (Fig 2) A total of 187 out of 489 
patients in the GSH cohort had AF but complete data sets regarding the CHA2DS2VASc risk 
factors were only available in 130 patients. 
Figure 1. Prevalence of AF in total cohort 










Table 1 summarises the baseline clinical characteristics of the entire cohort at the time of 
enrolment. The patients with AF were older than those in sinus rhythm (SR) (median age: 35 
years in AF and 25 years in SR, p <0.0001). Patients were also more likely to be female and 
have a history of congestive heart failure than those in SR (female gender: 73.1% in AF, 
65.7% in SR: p=0.001 and for a prior history of congestive heart failure: 41% in AF and 
33.3% in SR: p=0.001). The AF group had significantly more strokes or TIA’s compared to 
those in sinus rhythm and were more likely to have a NYHA III-IV effort tolerance. AF 
patients were more likely to have had previous interventions (both surgical and 
percutaneous), which may reflect more severe disease. No other significant differences were 
found between the two groups at baseline. 
Table	1:	Baseline	Clinical	Characteristics	for	total	cohort	at	time	of	enrollment	(n=	2,624)	




I	 685	(34.5)	 172	(29.3)	 0.002	
II	 808	(40.5)	 233	(39.7)	  
III	 408	(20.5)	 134	(22.7)	  
IV	 93	(4.7)	 48	(8.1)	  
NYHA	III&IV	 501	(25.2)	 182	(30.8)	 0.002	
	
	




Table 2 describes the frequency of each valve lesion within the AF cohort, as present on 
clinical examination. The majority of patients with AF had been diagnosed with mitral 
stenosis and regurgitation; less so were found to have aortic valve disease. As expected, only 
a small number of patients had clinical features of pulmonary valve disease. In total, 88 
(15.3%) were in overt heart failure at enrolment. 
Table	2:	Frequency	of	Clinical	Valve	lesions	in	the	total	AF	cohort	of	patients	(n=586)	
	
 Mild	 Moderate	 Severe	 n	
Mitral	Regurgitation	 145	(35.3)	 117	(28.5)	 149	(36.3)	 411	
Mitral	Stenosis	 78	(20.2)	 110	(28.5)	 198	(51.3)	 386	
Aortic	Regurgitation	 173	(57.8)	 92	(30.8)	 34	(11.4)	 299	
Aortic	Stenosis	 41	(47.1)	 25	(28.8)	 21	(24.1)	 87	
Tricuspid	Regurgitation	  152	(57.4)	 113	(42.6)	 265	
Tricuspid	Stenosis	 15	(51.7)	 5	(17.2)	 9	(31.0)	 29	
Pulmonary	Regurgitation	  13	(72.2)	 5	(27.8)	 18	








LVID	(Diastolic)	(med,	IQR)	N=2528	 49.8	(43.0-58.0)	 43.8	(50.0-59.0)	 0.1088	
LVID	(systolic)	(med,	IQR)	 33.0	(27.6-	40.0)	 35.0	(28.7-43.0)	 <0.0001	
LVEF	(med,	IQR)	N=2516	 61.0	(55.0-68.0)	 57	(49-65.0)	 <0.0001	
Decreased	EF	n	(%	yes)	N=2510	 457	(23.5)	 216	(38.4)	 <0.0001	
Dilate	LV	n	(%	yes)	 760	(38.7)	 206	(37.1)	 0.5060	
LA	Size	(med,	IQR)	 44.8		(36.8-53.0)	 55.0	(48.0-64.0)	 <0.0001	
LA	Thrombus	n	(%	yes)	 18	(0.9)	 20	(3.7)	 <0.0001	
Spontaneous	echo	contrast	 58	(3.0)	 42	(7.9)	 <0.0001	
	
	
Prosthetic valves had been implanted in 145 (34.7%) of those with AF. Of these, 94.5% were 
mechanical prosthetic valves. Compared to the SR group, those with AF were more likely to 
have dilated left atria [55 vs 44.8mm in AF compared to SR: p <0.0001] and a lower LV 
ejection fraction [EF 57 vs 61%: p < 0.0001]. Spontaneous echo contrast and LA thrombus 
was more frequently seen in the AF group. (Table 3) 
 
Just over 2/3 of patients (68%) with AF had been given a prescription for warfarin (Fig 3). A 
further 9.2% were given aspirin. More than a fifth of patients with significant valvular heart 






















The cohort of AF patients at the Groote Schuur Hospital, Cape Town was scored according to 
the CHADS2 and CHA2DS2VASc scores. Table 4 shows that half of patients have a CHADS2 
score of 0 or 1 signifying a low level of comorbidity. 
ANTICOAGULATION	USE	IN	ATRIAL	
FIBRILLATION	





















   Total	 130	 100%	
	
When the same cohort of patients was scored using the CHA2DS2Vasc score (Table 5), the 
score of 0 dropped from 23,1% to 5.4%, with considerably more patients scoring 2 or above. 
On assessment of the individual risk factors making up the CHA2DS2VASc score this 
difference appears to be driven mainly by the addition of a category for female gender. In 
contrast to non-valvular AF, most patients in our cohort were younger 65 years of age 




GSH cohort: Outcomes 
 
 
Table 6 shows the outcomes of death and stroke being significantly greater in the AF group 
compared to the SR group at 2-year follow-up – for deaths 13.1% vs 5.5% (p=0.016) and for 
stroke 4.6% vs 1.5% (p=0.09). 
  
Table	6:	At	2	year	Follow-up:	  
 N(%)	AF	 N(%)	Sinus	 Total	 P	
Deaths	 17	(13.1)	 11	(5.5)	 28	 0.016	
Stroke	 6	(4.6)	 3	(1.5)	 9	 0.09	
 
 
Figures 4 and 5 represent the Kaplan-Meier survival curves. It is evident in both the total 
REMEDY and GSH cohorts that the presence of AF at enrollment significantly reduces 
survival. From initial enrollment, the lines continue to diverge. In the total REMEDY cohort 
(Fig 4), there is a greater than 20% mortality at 2 years in the AF group. Even at a tertiary 
level center, (Fig 5) the mortality rate at 2 years is greater than 15%. The survival at 2 years  








Kaplan-Meier curves (figures 6 and 7) in the AF cohort demonstrated that the presence of any 
additional co-morbidities significantly reduces survival in both the short and long term. This 
was true for risk stratification by both the CHADS2 and CHA2DS2VASc scores. A CHADS2
score of 0 was still associated with a small number of events (Fig 6) but when the same group 
was re-stratified with the CHA2DS2VASc score, the ‘true low risk group’ with a score of 0 had 
no events (Fig 7). Greater CHA2DS2VASc score categories (CHA2DS2VASc 1 and 
CHA2DS2VASc 2 or more) conferred a higher risk of death.
Table	7:	Hazard	Ratios	for	deaths	according	to	the	various	CHADS2	and	CHA2DS2VASc	scores	
Predictor Hazard Ratio 95% Confidence Interval P Value 
CHADS2
CHADS2 of 1 4.35 0.95 – 19.83 0.058 
CHADS2 of 2 9.63 2.11 – 43.96 0.003 
CHADS2 of 3 6.49 1.08 – 38.87 0.040 
CHADS2 of 4 44.09 7.34 – 264.56 0.000 
Predictor Hazard Ratio 95% Confidence Interval P Value 
CHA2DS2VASc 
CHA2DS2VASc of 1 4.02 4.83 – 3.34 0.000 
CHA2DS2VASc of 2 3.66 4.41 – 3.04 0.000 
CHA2DS2VASc of 3 1.14 1.46 – 8.92 0.000 
CHA2DS2VASc of 4 3.56 0.000 
CHA2DS2VASc of 5 1.37 1.42 – 1.32 0.000 
CHA2DS2VASc of 6 6.79 6.14 – 7.50 0.000 
Table 7 describes the hazard ratios by CHADS2 and CHA2DS2VASc scores. All 
CHA2DS2VASc scores of one or greater is associated with a significant risk of death, though 
an incremental difference with each consecutive increasing score is not observed. This is 
















The stroke and death rate per CHA2DS2VASc category is depicted in Figure 8. A 
CHA2DS2VASc score of 1 or more confers significant risk of death and this is particularly 
marked if the score is 2 or more (p <0.0001). This observation holds true for strokes as well  







   
  
  
    
   
     
   










In this study, we assessed AF in a contemporary cohort of patients with rheumatic heart 





The prevalence of AF in this cohort was 22.3%. This is considerably higher than that of non- 
valvular AF where the prevalence reached around 8%16 in the ninth decade. For the GSH 
cohort – a tertiary referral center cohort – the prevalence was 38.2%. This higher prevalence 
compared to the overall REMEDY cohort most likely reflects a greater disease severity as 
evidenced by more interventional and surgical procedures in the tertiary center compared to 
those patients in the general community. Furthermore, the ECG’s of this entire cohort was re- 
assessed and verified as AF by a cardiologist. A number of patients with rhythms classified  
as ‘other’ were re-classified from paced rhythm or atrial flutter to AF when the underlying 
atrial rhythms were carefully scrutinized. In historic cohorts of RHD, the prevalence of AF 
ranged from 20 to 70% depending on disease severity or method and timing of sampling.1,2,17 
 
2. Baseline characteristics 
 
 
The median age of the GSH cohort was 28 (35 in the total cohort) and more than 70% were 
female, once again in keeping with previous RHD cohorts.1 AF patients had a greater history 
of heart failure, accompanied by a worse NYHA class, as well as a history of intervention, 
both percutaneous and surgical, once again reflecting increased disease severity in AF cohort. 
 
Most patients had mitral valve disease (regurgitation and stenosis) and at least two thirds had 
some degree of aortic regurgitation as well. Aortic stenosis was uncommon and pulmonary 
valve involvement rare. The LV diastolic dimensions on echo were not significantly different 
between the two groups, however the systolic dimensions were greater in the AF group, 
reflecting a reduced LV ejection fraction. The LA size was dramatically greater in the AF 
group with thrombus visualized in 3.7%. Though this number seems low, it is statistically 
more than in sinus rhythm cohort, but it is noted that transthoracic echo is not the most ideal 
modality to assess for LA thrombus since the left atrial appendage is poorly visualized on 
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transthoracic echo in adults and this would be where most thrombi form. Spontaneous echo 
contrast was seen in 7.9% of the AF cohort. 
Observational studies in valvular AF suggested long term oral anticoagulation as a method to 
prevent systemic emboli. In a review of 254 patients, Roy et al. found an embolic event rate 
of 5.46 per 100 patient years in patients with no anticoagulant therapy compared to 0.7 per 
100 patient years in those receiving oral anticoagulation.18 In our cohort, only 68% received a 
prescription for warfarin. A further 9% had aspirin. This however does not constitute 
appropriate anticoagulation in the setting of AF.19,20 Twenty-three percent of patients with 
valvular AF received no form of anticoagulation or antiplatelet therapy at all. We do not have 
data pertaining to the adequacy of anticoagulation or the reasons for non-prescription in these 
patients. The lack of adequate anticoagulation may well be an additional factor contributing 
to the high rates of stroke and death we observed at two years. In the GSH cohort, the  
survival seemed slightly better compared to the general cohort. This may reflect 
intensification of care and follow-up. 
3. CHADS2 and CHA2DS2VASC risk factors
The CHADS2 and CHA2DS2VASc scores for 130 of the AF patients in the GSH cohort were 
calculated. For the CHADS2 score, 23.1% had no additional risk factors for AF and 27.7% 
had a score of 1. When the CHA2DS2VASc score was applied to the same cohort, the score of 
0 dropped to only 5.4%. This difference was mainly driven by the addition of female gender 
as a risk factor. Forty percent of patients had a prior history of congestive heart failure and 
15% had a prior history of stroke or TIA. The frequencies of the other individual risk factors 
and comorbidities were low. This is likely due to this being a younger cohort when compared 
to non-valvular AF studies. 
4. Outcomes
We assessed the outcomes of stroke and death at two year follow-up. All forms of AF are 
known to increase morbidity and mortality significantly.21,22 Despite the low level of co- 
morbidity in terms of the individual risk factor profile and the younger age of the cohort in 
general, 4.6% strokes and 13.1% mortality were observed in the AF group at two years. This 
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was significantly greater than the group with sinus rhythm (1.5% strokes and 5.5% mortality 
at 2 years). In this setting, AF in its own right, without additional risk factors, dramatically 
increases morbidity and mortality. Thirty-five percent of patient with AF has prosthetic 
valves, the majority being mechanical valves. This was not corrected for in the outcomes 
assessments. 
The CHADS2 and CHA2DS2VASc scores were originally derived to assess the need for oral 
anticoagulation for stroke prevention in patients with non-valvular AF and validated in 
numerous studies.10,11 Scores of 2 or above were associated with worse outcomes in terms of 
stroke and in some studies, even mortality.23 Traditionally, the studies assessing the efficacy 
of the scoring systems excluded valvular AF, especially rheumatic patients, since they 
already represent a high-risk group. It is well established that RHD carries up to a 17-fold 
increased risk for stroke and warrants anticoagulation in its own right.3
In our study, the rates for both stroke and death increase incrementally and significantly with 
increasing score category (CHA2DS2VASc category 0, 1 or 2 or more). The sample size was 
too small to show any significant differences for each consecutive individual score category 
of 0-9. Though we cannot conclusively denote the role of these scoring systems in RHD in 
the decision to anticoagulate or not, we can conclude that the scoring systems have an 
important role in prognostication for stroke and mortality. This would hopefully drive stricter 
control of existing anticoagulation regimens and the development of potential new 
anticoagulation strategies in RHD. 
Study limitations 
This is a post-hoc review of the AF cohort of the REMEDY study. REMEDY is a hospital- 
based registry. Most of our participating centers are referral units, so it is likely that only the 
more severe cases of RHD are included in this study. This would therefore hamper the 
widespread generalization of these results to the entire AF community. The diagnosis of AF 
in the general cohort is on clinical and/or ECG grounds; at GSH, All ECG’s and Holter 
tracings were reviewed and true diagnosis of AF verified resulting in a larger total number of 




The data pertaining to the CHADS2 and CHA2DS2VASc scores were collected  
retrospectively – full data sets were only obtained in 130 patients. In light of this, the sample 
size is small when considering each CHA2DS2VASc category individually. Pertaining to the 
death and stroke rates, the confounders (e.g., the presence of prosthetic valves) were not 
accounted for. 
Furthermore, given the differences in chronicity between RHD in the developed world (i.e., 
disease of older people) and RHD in developing countries (i.e., disease of the young), these 
results cannot be extrapolated to those living in the first world. 
Conclusions 
In this study, we evaluated AF in a contemporary cohort of patient with RHD. We found a 
prevalence of 22% in the general cohort, and of 39% in a tertiary cohort. AF patients 
displayed clinical and echocardiographic features of more severe disease. The outcomes of 
stroke and mortality in the AF group were found to be 4.6% and 13.1 % respectively, despite 
these patients being young and having relatively few comorbidities. This was significantly 
greater than the stroke and death rates in the sinus rhythm group (1,5% and 5.5% 
respectively). Greater CHADS2 and CHA2DS2VASc scores were associated with significantly 
worse outcomes for stroke and death. Larger studies are required to determine the role of 
these scoring systems in the decisions around anticoagulation. 
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ADDENDUM 1: INFORMED CONSENT FORM 
 
 
1. STATEMENT BY THE PERSON AGREEING TO PARTICIPATE IN THIS STUDY 
 
 
I have read this Participant Information Sheet and informed consent document describing 
the benefits, risks and procedures for the research study titled “Global Registry of Rheumatic 
Heart Disease in Cape Town, South Africa” or it was read to me. I freely and voluntarily 
choose to participate in the study. 
Name of participant:________________________________________________________ 
 
 
Date: Signature or thumbprint of participant 
 
2. STATEMENT BY PARENT/GUARDIAN AGREEING FOR HIS/HER CHILD TO 
PARTICIPATE IN THIS STUDY 
 
 
I have read this Participant Information Sheet and informed  consent document describing 
the benefits, risks and procedures for the research study titled ““All Africa Registry of 
Rheumatic Heart Disease in Cape Town, South Africa” or it was read to me. I freely and 
voluntarily choose to allow my son/ daughter to participate in the study. 




Date Signature or thumbprint of parent/guardian 
 
3. IF THE PARENT/GUARDIAN CANNOT READ THE FORM THEMSELVES,  A 
WITNESS MUST SIGN HERE: 
 
 
I was present while the informed consent document with benefits, risks and procedures were 
read to the parent/guardian and the participant. The parent/guardian has freely and 




















We are doctors and nurses from Red Cross Childrens’, Groote Schuur Hospitals and 
Tygerberg Hospitals and we are doing a study of hearts of children. 
We would like to ask you a few questions about your health. This will not hurt at all and is 
very quick. 
If you agree to take part in this study, you will be helping doctors to know how better to treat 
other children in the future. 
You are allowed to say that you don’t want to be in the study. Nobody will be angry with you 
if you say no. 
Before you decide, you can ask us questions. If you want to be in the study, you must write 








Printed name Signature Date 
 
 












Printed name Signature Date 
 
 



























ADDENDUM 3:  
CHADS2 AND CHADS2VASc RISK FACTOR DATA SHEET 
CHADS2 score frequency of variables for GSH cohort 
Risk Factor Present Absent 
CHF (recent) 
Hypertension (history of) 




CHA2DSsVASc score frequency of variables for GSH cohort 
Risk factor Present Absent 
CHF/LV dysfunction 
Hypertension 
Age 75 or greater 
Diabetes Mellitus 
Stroke/TIA/TE 
Vascular disease (prior 
MI,PAD, or aortic plaque) 
Age 65-74 
Sex - female 
Maximum score 
ADDENDUM 4: FOLLOW-UP QUESTIONAIRES 
Global Registry of 
Rheumatic Heart Disease 
12 Month Visit Questionnaire 
INSTRUCTIONS 
Please complete Subject’s Initials on every page 
F= first letter of first name M= first letter of middle name 
L= first letter of last name 
Please answer EACH question by marking 
an X in ONE BOX on each line: 
(unless otherwise instructed) 
OR 
By writing number(s) in the spaces provided: 
OR 
By specifying the answer on the line(s) provided 










































Global Registry of 







Atrial Flutter/ Fibrillation 
INSTRUCTIONS 
 
Please complete Subject’s Initials on every page 
F= first letter of first name M= first letter of middle name 
L= first letter of last name 
Please answer EACH question by marking 
an X in ONE BOX on each line: 
(unless otherwise instructed) 
 
OR 
By writing number(s) in the spaces provided: 
 
OR 
By specifying the answer on the line(s) provided 
 
 
Version 1.1 - 01 Aug, 2011 
 
 















































Table 1: Stroke Risk Stratification with the CHADS2 Score 
Risk Factor Score CHADS2 Score Stroke rate, % 
CHF (recent) 1 0 1.9 
Hypertension (history of) 1 1 2.8 
Age 75 or older 1 2 4.0 
Diabetic Mellitus 1 3 5.9 
Stroke/TIA 2 4 8.5 
  5 12.5 
  6 18.2 




Table 2: Stroke Risk stratification with the CHA2DS2-VASc score 




CHF/LV dysfunction 1 0 0 
Hypertension 1 1 1.3 
Age 75 or greater 2 2 2.2 
Diabetes Mellitus 1 3 3.2 
Stroke/TIA/TE 2 4 4.0 
Vascular disease (prior 
MI,PAD, or aortic plaque) 
1 5 6.7 
  
Age 65-74 1 6 9.8 
Sex - female 1 7 9.6 
  8 6.7 
  9 15.2 
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